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Abstract: Familial hypercholesterolaemia (FH) is a common inherited cause of premature cardio-
vascular disease, but the majority of patients remain undiagnosed. The aim of this systematic
review was to assess the effectiveness of interventions to systematically identify FH in primary care.
No randomised, controlled studies were identified; however, three non-randomised intervention
studies were eligible for inclusion. All three studies systematically identified FH using reminders
(on-screen prompts) in electronic health records. There was insufficient evidence that providing
comments on laboratory test results increased the identification of FH using the Dutch Lipid Clinic
Network (DLCN) criteria. Similarly, using prompts combined with postal invitation demonstrated
no significant increase in definite FH identification using Simon-Broome (SB) criteria; however, the
identification of possible FH increased by 25.4% (CI 17.75 to 33.97%). Using on-screen prompts alone
demonstrated a small increase of 0.05% (95% CI 0.03 to 0.07%) in identifying definite FH using SB
criteria; however, when the intervention was combined with an outreach FH nurse assessment, the
result was no significant increase in FH identification using a combination of SB and DLCN criteria.
None of the included studies reported adverse effects associated with the interventions. Currently,
there is insufficient evidence to determine which is the most effective method of systematically
identifying FH in non-specialist settings.
Keywords: familial hypercholesterolaemia; primary care; genetics
1. Introduction
Familial hypercholesterolaemia (FH) is an autosomal-dominant disease and has long
been recognized as a cause of premature coronary heart disease (CHD) [1]. It is associated
with mutations in four genes: low-density lipoprotein (LDL) receptor, apolipoprotein B
(Apo B), proprotein convertase subtilin/kexin 9 (PCSK9) and low-density lipoprotein recep-
tor adaptor protein (LDLRAP) [2]. The majority of people with FH have the heterozygous
form, with an estimated prevalence up to 1 in 200 [1,3]. In the most recent studies, com-
pared to the general population, these patients have around a thirteen-fold increase in CHD
mortality [1,4]. FH can also be inherited in an homozygous form, albeit much more rarely,
with an estimated prevalence ranging from 1 in 160,000 to 1 in 1,000,000 individuals [2].
Further, a rarer autosomal-recessive form of the disease also exists [2]. Lipid-lowering
treatment reduces CHD mortality by 44% [5]. However, up to 80% of individuals with FH
remain undiagnosed and therefore untreated, resulting in major opportunities to prevent
premature heart disease [1,3,6].
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Several national guidelines on identifying FH have been published [7–13]. In these
guidelines, confirmation of FH diagnosis involves assessment against one or more specified
diagnostic criteria, such as the SimonBroome (SB) criteria [11], the USMedPed criteria [13],
the Dutch Lipid Clinic Network (DLCN) criteria [14–16], and the Japanese criteria [8].
Currently, individuals with FH are found incidentally in usual practice. It has been
suggested that a more systematic approach may help to identify more individuals in the
non-specialist setting [15,17,18].
The objective of this review is to assess the effectiveness of systematically identifying
FH in the adult primary care population, compared to usual care, to detect and manage
this condition.
2. Materials and Methods
This systematic review was conducted following the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions [19] and reported according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [20].
A related Cochrane protocol using more stringent study design inclusion criteria is reported
elsewhere [21].
2.1. Eligibility Criteria
2.1.1. Types of Study
We included randomised controlled trials (RCTs) and non-randomised intervention
studies, including, but not limited to, controlled and uncontrolled before and after studies.
We excluded non-randomised intervention studies, which did not report baseline data of
usual care (defined as incidental and non-systematic care during routine consultation with
participants [22]).
2.1.2. Types of Participant
We included adult participants (over 17 years old) who accessed primary care. Partici-
pants with a previous diagnosis of FH or other inherited lipid disorders were excluded.
2.1.3. Types of Intervention
We included any interventions that aimed to systematically identify people with pos-
sible or definite FH. Specialists delivering the interventions in primary care (e.g., FH nurse
specialists) were eligible for inclusion. Eligible comparators were usual care, including
incidental and non-systematic intervention during routine consultation with participants.
This includes noting a raised cholesterol during consultation with individuals presenting
with concerns about their personal or family history.
2.1.4. Types of Outcome Measure
Primary Outcomes:
• Diagnosis of definite FH (i.e., a positive genetic mutation or clinical characteristics of FH);
• Diagnosis of possible and probable FH (as defined by diagnostic criteria);
• Adverse events associated with the intervention.
Secondary Outcomes:
• Cholesterol levels;
• Cardiovascular mortality and morbidity (minimum of one-year follow-up);
• Lipid-lowering treatment;
• Referral to a specialist service;
• Adverse self-reported psychological effects.
2.2. Search Strategy
We identified relevant studies from a comprehensive search of seven electronic
databases, grey literature sources and Clinical Trials Registries. Additionally, we hand
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searched five major journals, two online resources from HEART UK [23] and the FH Foun-
dation [24], and relevant guideline developers (National Institute for Health and Care
Excellence [10], Scottish Intercollegiate Guidelines Network [25]) to identify further eligible
studies (Supplementary Materials Table S1 for full details).
2.3. Study Selection
Two authors independently screened the titles and abstracts of the studies identified
from the searches. The full texts of the potentially eligible studies were also screened
independently by two different authors, and reasons for exclusion at the full text stage
were noted. Any disagreements were resolved through discussion, or where necessary,
with the assistance of a third author.
2.4. Data Extraction
Two authors independently extracted data from included studies using a previously
piloted extraction form. The data extracted included author name, year of publication, char-
acteristics of the population, intervention, and comparator. Discrepancies were resolved
through discussion with a third author. Authors of the included studies were contacted
where additional information was required.
2.5. Risk of Bias Assessment
Two review authors independently assessed the risk of bias using the ROBINS-I tool
for non-randomised intervention studies [26]. A third author resolved disagreements.
2.6. Data Synthesis
Due to the small number of studies included in the review and the methodologi-
cal differences between them, this was limited to a narrative synthesis based on iden-
tifying patterns within the results of the studies. The results for comparison between
intervention and comparator groups for continuous outcomes are reported as mean dif-




The search identified a total of 4638 citations, of which 32 citations were identified
as potentially eligible based on title and abstract screening, representing 29 studies. Fol-
lowing full-text screening, three studies were eligible for inclusion into the review [27–29]
(Figure 1: PRISMA diagram). Thus, 25 studies were excluded from the review at the full
text stage. The reasons for exclusion were no baseline data of usual care (17 studies [30–46]),
ineligible participants (7 studies [47–53]) and ineligible condition (1 study [54]). There was
also one ongoing study [55]. Details on the 17 studies excluded based on study design (no
baseline data of usual care) are included as Supplementary Materials Table S2.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) diagram. 
3.2. Characteristics of Included Studies  
The three included studies were published between 2013 and 2018 (basic details in 
Table 1, with full details in Supplementary Materials Table S3). Two studies [28,29] were 
carried out in the United Kingdom, and the remaining study [27] was conducted in Aus-
tralia. All three primary care studies used an uncontrolled before-and-after study design. 
A total of 281,869 participants were involved in the studies, although the vast majority of 
participants were from one study [28]. The other two studies included a relatively small 
number of participants: 96 [27] and 118 [29]. 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) diagram.
3.2. Characteristics of Included Studies
The three included studies were published between 2013 and 2018 (basic details
in Table 1, with full details in Supplementary Materi ls T ble S3). Two studies [28,29]
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Table 1. Summary of included studies.
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The interventions assessed within the three included studies focused on systemati-
cally identifying participants through electronic health record (EHR) searches and using
computer reminders; however, the modalities varied between studies. In two studies, the
computer reminders were on-screen prompts for participants who had raised cholesterol
recorded within their EHR [28,29]. The Weng study [29] also incorporated postal invitations
to be assessed for FH by completing a family history questionnaire. Additionally, in the
follow-up phase of the Green study [28], a combined intervention of on-screen prompts
with an invitation for clinical assessment by a specialist FH nurse was also assessed. In the
third study, the computer reminder was an on-screen prompt in the downloaded laboratory
results [27].
The three studies made a diagnosis of definite, probable and possible FH based on
either the Simon-Broome criteria [28,29] or a modified version of the DLCN criteria (where
only participants with LDL-C ≥ 6.5 mmol/L were selected) [27]. However, in the follow-up
phase of the Green study [28], a diagnosis of FH was based on using a combination of the
Simon-Broome and/or DLCN criteria.
The overall risk of bias for all three of the included studies was low [27,29], including
the EHR reminder phase in Green [28]; however, for the combined intervention of com-
puter on-screen prompts and FH nurse intervention in the follow-up phase of the Green
study [28], the overall risk of bias was moderate to account for the risk of attrition bias due
to missing outcome data for some participants (data could not be extracted for 62,684 out
of 262,030 participants) (Supplementary Materials Table S3).
3.2.1. Diagnosis of Definite FH
All included studies reported the number of participants identified with definite FH.
In the Green study, systematically identifying participants in the EHRs using on-screen
prompts found a small absolute improvement in the proportion of participants diagnosed
with FH with the prevalence increasing from 0.13% to 0.18% over the two years of the
intervention period (SB criteria: MD 0.05%, 95% CI 0.03 to 0.07%) [28]. Additionally,
during the follow-up phase of this study, combining on-screen prompts in the EHR with
an invitation to an assessment with a specialist FH nurse, led to a further marginal increase
in prevalence of definite FH to 0.19% (SB criteria: MD 0.07%, 95% CI 0.05 to 0.09%).
In the Weng study, it was found that systematically identifying participants in EHRs
using on-screen prompts and postal invitations to complete family history questionnaires
may slightly increase the number of patients diagnosed with definite FH (SB criteria: 0
at baseline versus 2 diagnoses 6 months post-intervention; MD 1.69%, 95% CI –1.69% to
5.97%) [29].
Similarly, in the Bell study, it was found that systematically identifying participants
in EHRs using on-screen prompts within the laboratory results may slightly increase the
number of diagnoses with definite FH (modified DLCN criteria: 0 versus 2 diagnoses
4 months post-intervention; MD 2.08%, 95% CI –2.05% to 7.28%) [27]. Both diagnoses in
this study had an identifiable LDL-receptor gene mutation on genetic testing.
3.2.2. Diagnosis of Possible and Probable FH
Systematically identifying participants in EHRs, using on-screen prompts, found a
small absolute improvement in the proportion of participants diagnosed with possible
FH from the baseline (SB criteria: MD 0.04%, 95% CI 0.03% to 0.05%) [28]. Additionally,
combining on-screen prompts in the EHR with an invitation for a specialist FH nurse
assessment had an added small absolute improvement in the diagnosis of possible FH
from the baseline (SB criteria: MD 0.02%, 95% CI 0.02% to 0.03%) [28].
In contrast, using on-screen prompts in EHRs, combined with postal invitations to
complete family history questionnaires, resulted in a 25% absolute improvement in the
identification of possible FH (SB criteria: 0 at baseline versus 30 cases post-intervention;
MD 25.42%, 95% CI 17.75% to 33.97%) [29].
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However, systematically identifying participants in EHRs using on-screen prompts
in the laboratory results did not increase the diagnosis of probable FH (modified DLCN
criteria: MD 2.08%, 95% CI –2.05% to 7.28%) [27].
3.2.3. Adverse Events Associated with the Intervention
None of the included studies reported adverse events.
3.2.4. Cholesterol Levels
In the Weng study, there was no significant reduction in total cholesterol in the
intervention group compared to the baseline (total cholesterol: MD –0.16, 95% CI –0.78
to 0.46) [29]. There were mixed results for LDL cholesterol in the Weng study, with no
significant changes (LDL-C: MD –0.12, 95% CI –0.81 to 0.57) [29]. However, the Bell study
found a significant decrease 12 months after intervention (LDL-C: MD –3.00, 95% CI –3.42
to –2.58) [27].
3.2.5. Cardiovascular Mortality and Morbidity
None of the included studies reported this outcome measure.
3.2.6. Lipid-Lowering Treatment
Using on-screen prompts in EHRs, combined with postal invitations to complete
family history questionnaires, resulted in an absolute increase of 19% in the prescribing of
statins (MD 18.75%, 95% CI 8.9% to 35.3%), and an absolute increase of 9% in the prescribing
of high potency statins (MD 9.38%, 95% CI 3.2% to 24.2%), compared to the baseline [29].
3.2.7. Referral to a Specialist Service
One study reported that systematically identifying participants in EHRs using on-
screen prompts in the laboratory result resulted in 4% (4/96) of participants being referred
to a specialist service; however, at baseline, outcome data were not reported [27].
3.2.8. Adverse Self-Reported Psychological Effects
None of the included studies reported this outcome measure.
4. Discussion
This is the first systematic review to assess the effectiveness of interventions to sys-
tematically identify FH in primary care. The review included three studies, comprising
a total of 281,869 participants; however, the vast majority of participants were from one
study [28]. The included studies used on-screen prompts in electronic health records
to systematically identify individuals with raised cholesterol; one study combined this
with postal invitations to complete family history questionnaires [29] and another study
combined the intervention with the invitation for clinical assessment by an FH specialist
nurse [28]. A small absolute improvement in the identification of individuals with definite
FH was seen in one study [28]; however, no significant evidence of an effect was seen in the
other two studies. Given that FH is a relatively rare condition and studies were undertaken
in a few general practices, it is not surprising that the absolute improvement in detecting
the condition is quite small.
As the target populations within the included studies varied, it was difficult to estab-
lish direct comparisons between the three studies. Green [28] assessed the whole practice
population, whilst Bell [27] and Weng [29] had a pre-selected sample based on specific
case-finding criteria.
Improvements in the detection of possible FH with on-screen prompts varied between
studies. One study, when combined with postal invitations to complete a family history
questionnaire, demonstrated a larger absolute improvement [29], whilst another studies’
prompts, with or without FH specialist nurse assessment, found small improvement [28].
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However, using on-screen prompts in downloaded laboratory results demonstrated no
improvement [27].
Further, on-screen prompts had no significant effect on total cholesterol and only
one study showed a significant decrease in LDL-cholesterol levels [27]; an increase in
the prescribing of statins and high potency statins was demonstrated after introducing
on-screen prompts with postal invitations to complete family history questionnaires [29].
The number of participants clinically diagnosed with FH was relatively small across
the three included studies, which makes it difficult to ascertain the effectiveness of the
systematic identification as there will be limited power within the analyses. Furthermore,
several of the pre-specified primary and secondary outcome measures were not assessed
within the studies and, additionally, the length of follow-ups was too short to evaluate
cardiovascular disease outcome measures.
As one of the included studies had been undertaken by some of the review authors,
to avoid bias, two independent reviewers extracted the data and assessed for risk of bias.
Two of the included studies were deemed to have a low overall risk of bias; however, the
inherent biases associated with the design of non-randomised intervention studies means
that they are not optimal for assessing the effectiveness of the intervention.
There have been no previous published systematic reviews on this topic. However,
there have been several narrative reviews on the detection of FH in primary care. For
example, Lan et al. [56] outlines different screening methods for FH, including primary
care Electronic Health Records searches.
The updated (English) NICE guidelines on FH identification suggest that clinicians
should systematically search primary care Electronic Health Records for individuals at
risk of FH [10]. One of the studies [28] included in the current review also informed
the recommendations in the NICE guideline. Other studies listed in the updated NICE
guideline as evidence for the use of Primary Care Electronic Health Records were also part
of our search results. However, these studies were excluded from the current systematic
review as they did not provide baseline data on usual care to allow an assessment of
improvement in outcome measures [32,38,40,41,44].
Further high-quality, controlled studies, ideally in the form of randomised, controlled
trials, are needed before a firm conclusion regarding the most effective approach to system-
atically identifying individuals at risk of FH. Furthermore, to fully address this research
question, studies should use recognised clinical assessment criteria for the diagnosis of FH
and, if possible, genetic confirmation of FH. Future studies should provide detailed de-
scriptions of the relevant process and outcome measures, including detection of genetically
confirmed FH and both surrogate and clinical outcome measures of cardiovascular disease.
The review provided insufficient evidence to recommend specific systematic ap-
proaches to identify individuals at increased risk of FH. However, this does indicate the
clinical value of searching primary care Electronic Health Records (EHR). The simplest
iteration of this is searching the records for individuals with raised cholesterol, and more
elaborate methods of searching primary care EHR are being developed [57]. Further,
automated alerts to identify patients at increased risk, based on cholesterol levels, have
been developed. The latter approach is already a recognized strategy in primary care; for
example, haematology reports alerting clinicians to screen for thalassaemia traits when a
microcytic, hypochromic blood profile is identified.
5. Conclusions
This systematic review provided insufficient evidence to inform the most effective
approach to identify FH in primary care. There is a potential role for searching primary
care Electronic Health Records, but further studies need to be conducted.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jpm11040302/s1, Table S1: Search Strategy; Table S2: Table of excluded studies; Table S3:
Characteristics of included studies.
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